It was reported that a patient underwent a myomectomy procedure on (b)(6) 2022 and barbed suture was used.During the procedure, the doctor used suture to sew the stripped surface of uterine leiomyoma.When the suture reached about 2/3 of the uterine wound the suture was broken, causing the patient's uterine wound to rupture and oozing.Changed another one to complete the surgery.No adverse patient consequences were reported.Additional information was requested.
|
Product complaint # (b)(4).This is a combination product, and the event has been reviewed for both the suture and the triclosan.This report is being submitted pursuant to the provisions of 21 cfr, part 803, part 4 subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.To date the device has not been returned.If the device or further details are received at a later date a supplemental medwatch will be sent.The following information was requested, but unavailable: what is meant by uterine wound to rupture? was the uterine wound rupture and oozing controlled intra-op with re-suturing with a new suture? was any medical or surgical intervention required for the event other than using a new suture to complete the procedure? was the patient¿s treatment or post-operative care altered in anyway due to suture breaking intra-op? if yes, please explain.Was there any patient impact (ie.Additional treatment required) and/or adverse patient outcome due to the suture breakage intra-op? were there any adverse patient consequences? what is the patient¿s current status? a manufacturing record evaluation was performed for the finished device lot, and no non-conformances were identified.Trade name - irgacare®.Active ingredient(s) ¿ triclosan.Dosage form ¿ suture/solid/parenteral.Strength ¿ = 2360 ¿g/m.
|